Quick Links

Experimental MS vaccine proves safe in early trial

News

Published: 13 Aug 2007

An experimental DNA vaccine to fight multiple sclerosis is safe and may also be effective, results of a small McGill trial suggest. The vaccine, called BHT-3009, works by preventing the immune system from attacking the myelin sheaths that protect nerve cells in the brain and spinal cord. "This was an early trial of a new class of drugs for autoimmune disease in general and for MS in particular," said lead researcher Dr. Amit Bar-Or, of McGill's Montreal Neurological Institute. The findings were published online Monday in Archives of Neurology and are expected to be published in the October print issue of the journal.

An experimental DNA vaccine to fight multiple sclerosis is safe and may also be effective, results of a small McGill trial suggest. The vaccine, called BHT-3009, works by preventing the immune system from attacking the myelin sheaths that protect nerve cells in the brain and spinal cord. "This was an early trial of a new class of drugs for autoimmune disease in general and for MS in particular," said lead researcher Dr. Amit Bar-Or, of McGill's Montreal Neurological Institute. The findings were published online Monday in Archives of Neurology and are expected to be published in the October print issue of the journal.
Source Site: /newsroom
Classified as: